These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 20053775)

  • 1. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
    Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
    Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies.
    Chinn DC; Holland WS; Mack PC
    J Cancer Res Clin Oncol; 2014 Jul; 140(7):1137-49. PubMed ID: 24756365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
    Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
    Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
    Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
    Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
    Shan W; Akinfenwa PY; Savannah KB; Kolomeyevskaya N; Laucirica R; Thomas DG; Odunsi K; Creighton CJ; Lev DC; Anderson ML
    Clin Cancer Res; 2012 Jun; 18(12):3352-65. PubMed ID: 22535157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.
    Lin YG; Immaneni A; Merritt WM; Mangala LS; Kim SW; Shahzad MM; Tsang YT; Armaiz-Pena GN; Lu C; Kamat AA; Han LY; Spannuth WA; Nick AM; Landen CN; Wong KK; Gray MJ; Coleman RL; Bodurka DC; Brinkley WR; Sood AK
    Clin Cancer Res; 2008 Sep; 14(17):5437-46. PubMed ID: 18765535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
    Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
    Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
    Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
    Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
    Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
    Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
    Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
    In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
    Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
    Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
    Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
    Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D
    Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
    Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
    Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
    Farrell P; Shi L; Matuszkiewicz J; Balakrishna D; Hoshino T; Zhang L; Elliott S; Fabrey R; Lee B; Halkowycz P; Sang B; Ishino S; Nomura T; Teratani M; Ohta Y; Grimshaw C; Paraselli B; Satou T; de Jong R
    Mol Cancer Ther; 2013 Apr; 12(4):460-70. PubMed ID: 23358665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.
    Wang S; Midgley CA; Scaërou F; Grabarek JB; Griffiths G; Jackson W; Kontopidis G; McClue SJ; McInnes C; Meades C; Mezna M; Plater A; Stuart I; Thomas MP; Wood G; Clarke RG; Blake DG; Zheleva DI; Lane DP; Jackson RC; Glover DM; Fischer PM
    J Med Chem; 2010 Jun; 53(11):4367-78. PubMed ID: 20462263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.
    Amin M; Minton SE; LoRusso PM; Krishnamurthi SS; Pickett CA; Lunceford J; Hille D; Mauro D; Stein MN; Wang-Gillam A; Trull L; Lockhart AC
    Invest New Drugs; 2016 Feb; 34(1):84-95. PubMed ID: 26620496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors.
    Basso AD; Liu M; Gray K; Tevar S; Lee S; Liang L; Ponery A; Smith EB; Monsma FJ; Yu T; Zhang Y; Kerekes AD; Esposite S; Xiao Y; Tagat JR; Hicklin DJ; Kirschmeier P
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):923-33. PubMed ID: 21298383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.
    Fiskus W; Hembruff SL; Rao R; Sharma P; Balusu R; Venkannagari S; Smith JE; Peth K; Peiper SC; Bhalla KN
    Breast Cancer Res Treat; 2012 Sep; 135(2):433-44. PubMed ID: 22825030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
    Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
    Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.